By the end of 2018, there has been no China-made Rituximab on the market, and the market is monopolized by the products of Roche and its subsidiary Genentech. However, starting in 2019 ...
-
-
Recent Updates
- RELEX Brings AI Supply Chain Tools to China Convenience Store Chain Tangjiu
- Alleged Huang Relationship Draws National Security Concern After Taipei Sighting
- Nvidia Chief’s Alleged Chinese Spy Affair Tests Washington’s AI Race with China
- Jensen Huang’s China Chip Pitch Faces a Sudden Reckoning
- Nvidia Investor Suit Ties China Spy Allegations to Stock Drop
- Audi Holds Off on China Sourcing for Australia as Volkswagen Looks East
- Nvidia Chip Pitch Tied to China Scrutiny as Alice Huang Cited Alibaba
- CNBC’s The China Connection newsletter: Wall Street dips in again. What needs to go right
- SGS and EcoFlow Advance Battery Passports at China Import Expo
- AXA Tianping Deepens China Role as Lingang Backs Smart Vehicle Push Into Brazil
Blogroll